Associating Violence With Schizophrenia - Risks and Biases

Paolo Fusar-Poli; Charlene Sunkel; Vikram Patel

doi:10.1001/jamapsychiatry.2022.0939

Associating Violence With Schizophrenia - Risks and Biases

Paolo Fusar-Poli^*, Charlene Sunkel, Vikram Patel

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

2 Citations (Scopus)

Original language	English
Pages (from-to)	738-739
Number of pages	2
Journal	JAMA Psychiatry
Volume	79
Issue number	7
DOIs	https://doi.org/10.1001/jamapsychiatry.2022.0939
Publication status	Published - Jul 2022

Access to Document

10.1001/jamapsychiatry.2022.0939

Cite this

@article{9ae6cdd4ec4e4ca8ad30df0bacf89eef,

title = "Associating Violence With Schizophrenia - Risks and Biases",

author = "Paolo Fusar-Poli and Charlene Sunkel and Vikram Patel",

note = "Funding Information: EMA Wellness, Engrail Therapeutics, Clexio, Denovo Biopharma, Gilgamesh, Hoffmann La-Roche, Intra-Cellular Therapies, Janssen Pharmaceuticals, Levo, Lundbeck, Merck, Navitor Pharmaceuticals, Neurocrine, Novartis, Noven Pharmaceuticals, Otsuka, Perception Neuroscience, Praxis Therapeutics, Sage Pharmaceuticals, Servier Pharmaceuticals, Seelos Pharmaceuticals, Taisho Pharmaceuticals, Teva, Valeant, Vistagen Therapeutics, and XW Labs. Dr Sanacora also reported receiving research contracts from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, and Usona over the past 36 months. Dr. Sanacora holds equity in Biohaven Pharmaceuticals and is a co-inventor on a US patent (8,778,979) held by Yale University and a co-inventor on US Provisional Patent Application 047162-7177P1 (00754) filed on August 20, 2018, by the Yale University Office of Cooperative Research. Yale University has a financial relationship with Janssen Pharmaceuticals and may in the future receive financial benefits from this relationship. The university has put multiple measures in place to mitigate this institutional conflict of interest. Questions about the details of these measures should be directed to Yale University{\textquoteright}s Conflict of Interest office. Dr Wilkinson reported receiving contract funding from Janssen Pharmaceuticals, Sage Therapeutics, and Oui Therapeutics for the conduct of clinical trials administered through Yale University as well as consulting fees from Biohaven Pharmaceuticals, Sage Therapeutics, Janssen Pharmaceuticals, and Oui Therapeutics. No other disclosures were reported. Funding Information: Funding/Support: There was no direct funding for this study. However, the Yale Psychiatric Hospital provided indirect funding that allowed the Interventional Psychiatric Service to treat patients with ketamine in a clinical setting before most third-party payers began reimbursing for this service. In addition, funding through support was provided in part by the George D. Gross and Esther S. Gross Endowment (Dr Sanacora) and the Yale New Haven Health System (Drs Nikayin, Sanacora, and Wilkinson).",

year = "2022",

month = jul,

doi = "10.1001/jamapsychiatry.2022.0939",

language = "English",

volume = "79",

pages = "738--739",

journal = "JAMA Psychiatry",

issn = "2168-622X",

publisher = "American Medical Association",

number = "7",

}

TY - JOUR

T1 - Associating Violence With Schizophrenia - Risks and Biases

AU - Fusar-Poli, Paolo

AU - Sunkel, Charlene

AU - Patel, Vikram

N1 - Funding Information: EMA Wellness, Engrail Therapeutics, Clexio, Denovo Biopharma, Gilgamesh, Hoffmann La-Roche, Intra-Cellular Therapies, Janssen Pharmaceuticals, Levo, Lundbeck, Merck, Navitor Pharmaceuticals, Neurocrine, Novartis, Noven Pharmaceuticals, Otsuka, Perception Neuroscience, Praxis Therapeutics, Sage Pharmaceuticals, Servier Pharmaceuticals, Seelos Pharmaceuticals, Taisho Pharmaceuticals, Teva, Valeant, Vistagen Therapeutics, and XW Labs. Dr Sanacora also reported receiving research contracts from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, and Usona over the past 36 months. Dr. Sanacora holds equity in Biohaven Pharmaceuticals and is a co-inventor on a US patent (8,778,979) held by Yale University and a co-inventor on US Provisional Patent Application 047162-7177P1 (00754) filed on August 20, 2018, by the Yale University Office of Cooperative Research. Yale University has a financial relationship with Janssen Pharmaceuticals and may in the future receive financial benefits from this relationship. The university has put multiple measures in place to mitigate this institutional conflict of interest. Questions about the details of these measures should be directed to Yale University’s Conflict of Interest office. Dr Wilkinson reported receiving contract funding from Janssen Pharmaceuticals, Sage Therapeutics, and Oui Therapeutics for the conduct of clinical trials administered through Yale University as well as consulting fees from Biohaven Pharmaceuticals, Sage Therapeutics, Janssen Pharmaceuticals, and Oui Therapeutics. No other disclosures were reported. Funding Information: Funding/Support: There was no direct funding for this study. However, the Yale Psychiatric Hospital provided indirect funding that allowed the Interventional Psychiatric Service to treat patients with ketamine in a clinical setting before most third-party payers began reimbursing for this service. In addition, funding through support was provided in part by the George D. Gross and Esther S. Gross Endowment (Dr Sanacora) and the Yale New Haven Health System (Drs Nikayin, Sanacora, and Wilkinson).

PY - 2022/7

Y1 - 2022/7

UR - http://www.scopus.com/inward/record.url?scp=85129886103&partnerID=8YFLogxK

U2 - 10.1001/jamapsychiatry.2022.0939

DO - 10.1001/jamapsychiatry.2022.0939

M3 - Letter

AN - SCOPUS:85129886103

SN - 2168-622X

VL - 79

SP - 738

EP - 739

JO - JAMA Psychiatry

JF - JAMA Psychiatry

IS - 7

ER -

Associating Violence With Schizophrenia - Risks and Biases

Access to Document

Other files and links

Cite this